Overview

Study to Assess Safety, Tolerability and Immune Response of Fimaporfin-induced Photochemical Internalisation of Antigen/Adjuvant

Status:
Completed

Trial end date:
2018-03-26

Target enrollment:

Participant gender:

Summary

Fimaporfin (TPCS2a) is a photosensitiser drug being developed by PCI Biotech AS for use in novel Photochemical Internalisation (PCI) technology. PCI technology is designed to enhance the effects of other drugs in a site-specific, light-directed manner and is used to re-localise endocytosed molecules from endosomes to cytosol. This research study is evaluating the use of the PCI Technology in combination with adjuvant and vaccine antigens for safety and induction of immune responses.

Phase:

Phase 1

Details

Lead Sponsor:

PCI Biotech AS

Treatments:

Keyhole-limpet hemocyanin
Photosensitizing Agents
Poly ICLC